20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Ambrx Biopharma Inc's (NYSE:AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-Breast-01 Phase 1 study of ARX788 at the San Antonio Breast Cancer Symposium (SABCS).
- ARX788 demonstrated treatment effect among patients who previously failed a median of seven anti-HER2 targeting therapies.
- ARX788 demonstrated robust anti-tumor activity, with a disease control rate of 100% in the 29 patients treated at 1.5 mg/kg Q3W.
- One patient who received prior pertuzumab also achieved confirmed partial response (PR).
- The disease control rate among evaluable patients in the 1.5 mg/kg cohort was 100% (29/29).
- ARX788 demonstrated low systemic toxicity and was generally well-tolerated, with most adverse events being grade 1 or 2. No dose-limiting toxicity or drug-related deaths occurred.
- Price Action: AMAM shares are up 11.50% at $9.18 during the market session on the last check Thursday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!